Skip to main content
Log in

The Correct Administration of Antihypertensive Drugs According to the Principles of Clinical Pharmacology

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Control of cardiovascular (CV) risk factors, particularly hypertension, is still unsatisfactory, resulting in excess CV morbidity and mortality worldwide. CV risk is linearly associated with an increase in blood pressure (BP) values, and clinical studies have clearly demonstrated that BP lowering represents the most effective means of preventing CV events. However, while BP reduction is a fairly easy target, BP normalization is much more difficult to achieve, and adequate BP control (<140/90 mmHg) is attained only in a small percentage of the hypertensive population.

One of the main reasons for the lack of efficacy of antihypertensive pharmacological treatment is that very often drugs are not administered at the correct dosage. In this review, we discuss the importance of using clinical pharmacology to guide treatment of hypertension.

Controlled clinical trials, including HOPE, EUROPA, and CONSENSUS, are used to guide prescribing decisions. Unfortunately, the results obtained in pivotal studies such as these have been obtained using drug dosages much higher than those usually used in clinical practice. The prescription of a drug for the treatment of hypertension should take into consideration the potency of the drug, i.e. the degree of BP reduction required, and the duration of action of the drug, i.e. the need to cover the dosing interval (possibly 24 hours) in a homogeneous way.

This is especially the case for angiotensin-converting enzyme (ACE) inhibitors, compounds characterized by a flat dose-response curve. The significance of this flat dose-response curve is that a low dose of an ACE inhibitor has the same potency as a high dose but a shorter duration of action. If a low dosage is administered to a hypertensive patient it causes BP fluctuations, which have been associated with negative CV outcomes.

In contrast, other drug classes, including calcium channel antagonists, diuretics, and b-adrenoceptor antagonists, can be used at different dosages in order to modulate their hemodynamic effects.

Thus, it is important to be aware of the clinical pharmacology of antihypertensive drugs in order to choose not only the class or the molecule best suited to the clinical characteristics of the patient, but also the correct dosages to ensure effective and homogeneous 24-hour BP reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Fig. 3
Table II
Fig. 4

Similar content being viewed by others

References

  1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367(9524): 1747–57.

    Article  PubMed  Google Scholar 

  2. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373(9667): 929–40.

    Article  PubMed  Google Scholar 

  3. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360(9343): 1347–60.

    Article  PubMed  Google Scholar 

  4. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903–13.

    Article  PubMed  Google Scholar 

  5. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362(9395): 1527–35.

    Article  PubMed  CAS  Google Scholar 

  6. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6): 1105–87.

    Article  PubMed  CAS  Google Scholar 

  7. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27(11): 2121–58.

    Article  PubMed  CAS  Google Scholar 

  8. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365(9455): 217–23.

    PubMed  Google Scholar 

  9. Mancia G, Pessina AC, Trimarco B, et al. Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22(12): 2387–96.

    Article  PubMed  CAS  Google Scholar 

  10. Ezzati M, Oza S, Danaei G, et al. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation 2008; 117(7): 905–14.

    Article  PubMed  Google Scholar 

  11. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20(8): 1461–4.

    Article  PubMed  CAS  Google Scholar 

  12. Ghiadoni L, Bruno RM, Stea F, et al. Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr Hypertens Rep 2009; 11(3): 190–6.

    Article  PubMed  Google Scholar 

  13. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51(6): 1403–19.

    Article  PubMed  CAS  Google Scholar 

  14. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429–35.

    Article  Google Scholar 

  15. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53.

    Article  PubMed  CAS  Google Scholar 

  16. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782–8.

    Article  PubMed  CAS  Google Scholar 

  17. Salvetti A, Di Venanzio L, Arrighi P, et al. Trough:peak ratio of the blood pressure response to angiotensin converting enzyme inhibitors? J Hypertens 1994 Suppl.; 12(8): S91–4; discussion S94–5.

    CAS  Google Scholar 

  18. Parati G, Pomidossi G, Albini F, et al. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987; 5(1): 93–8.

    Article  PubMed  CAS  Google Scholar 

  19. Frattola A, Parati G, Cuspidi C, et al. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993; 11(10): 1133–7.

    Article  PubMed  CAS  Google Scholar 

  20. Frick MH, McGibney D, Tyler HM. A dose-response study of amlodipine in mild to moderate hypertension. J Intern Med 1989; 225(2): 101–5.

    Article  PubMed  CAS  Google Scholar 

  21. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43(1): 4–9.

    Article  PubMed  CAS  Google Scholar 

  22. Elliott HL, Meredith PA, Vincent J, et al. Clinical pharmacological studies with doxazosin. Br J Clin Pharmacol 1986; 21 Suppl. 1: 27S–31S.

    Article  PubMed  CAS  Google Scholar 

  23. Salvetti A, Di Venanzio L. Clinical pharmacology of long-acting calcium antagonists: what relevance for therapeutic effects? J Cardiovasc Pharmacol 1994; 23 Suppl. 5: S31–4.

    Article  PubMed  CAS  Google Scholar 

  24. Davies RO, Gomez HJ, Irvin JD, et al. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 1984; 18 Suppl. 2: 215S–29S.

    Article  PubMed  Google Scholar 

  25. Smith DH. Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists. Am J Cardiovasc Drugs 2007; 7(5): 347–56.

    Article  PubMed  CAS  Google Scholar 

  26. Remme WJ, McMurray JJ, Hobbs FD, et al. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J 2008; 29(14): 1739–52.

    Article  PubMed  Google Scholar 

  27. Drugs.com: drug information online. Enalapril [online]. Available from URL: http://www.drugs.com/pro/enalapril-tablets.html [Accessed 2010 Nov 1].

  28. Drugs.com: drug information online. Ramipril [online]. Available from URL: http://www.drugs.com/pro/ramipril.html [Accessed 2010 Nov 1].

  29. Neutel JM. Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 2004; 18(9): 599–606.

    Article  PubMed  CAS  Google Scholar 

  30. Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators’ Group? J Hypertens 1997; 15(12 Pt 1): 1511–8.

    Article  PubMed  CAS  Google Scholar 

  31. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7 Suppl. 1: S52–5.

    Article  PubMed  Google Scholar 

  32. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24(1): 3–10.

    Article  PubMed  CAS  Google Scholar 

  33. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906.

    Article  PubMed  Google Scholar 

  34. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23): 2417–28.

    Article  PubMed  CAS  Google Scholar 

  35. Salvetti A, Innocenti PF, Iardella M, et al. Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study. J Hypertens Suppl. 1987; 5(4): S139–42.

    Article  PubMed  CAS  Google Scholar 

  36. Chatzikyrkou C, Haller H, Menne J. The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril? Expert Opin Pharmacother 2009; 10(11): 1833–40.

    Article  PubMed  CAS  Google Scholar 

  37. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008; 8(1): 45–50.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Claire Byrne, from inScience Communications (a Wolters Kluwer business), who provided native English language assistance. This assistance was funded by Recordati.

Prof. Taddei has received honoraria for serving on the speakers bureau for: Servier International, Boehringer Ingelheim, Menarini, Recordati International, Sanofi-Aventis, and Pfizer. Dr Ghiadoni has received honoraria for serving on the speakers bureau for Recordati and Servier. Dr Bruno has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stefano Taddei.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taddei, S., Bruno, R.M. & Ghiadoni, L. The Correct Administration of Antihypertensive Drugs According to the Principles of Clinical Pharmacology. Am J Cardiovasc Drugs 11, 13–20 (2011). https://doi.org/10.2165/11586670-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11586670-000000000-00000

Keywords

Navigation